Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome

Molecular Immunology

Volumn 67, Issue 2, 2015, Pages 276-286

  Bernabéu Herrero, Maria E ^a,c   Jiménez Alcázar, Miguel ^a,d   Anter, Jaouad ^b,c   Pinto, Sheila ^b,c   Sánchez Chinchilla, Daniel ^b,c   Garrido, Sofía ^a,c   López Trascasa, Margarita ^a,c   Rodríguez de Córdoba, Santiago ^b,c   Sánchez Corral, Pilar ^a,c  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Atypical hemolytic uremic syndrome; Complement; Factor H; Factor H related protein 1; Factor H related protein 3; Haplotypes

Indexed keywords

AUTOANTIBODY; COMPLEMENT FACTOR H; FACTOR H RELATED PROTEIN 1; FACTOR H RELATED PROTEIN 3; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; CFHR1 PROTEIN, HUMAN; CFHR3 PROTEIN, HUMAN; COMPLEMENT FACTOR I; PLASMA PROTEIN;

ARTICLE; BLOOD SAMPLING; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HEMOLYTIC UREMIC SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; RISK ASSESSMENT; WESTERN BLOTTING; ADOLESCENT; ADULT; CHILD; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; INFANT; KIDNEY; MOLECULAR GENETICS; MUTATION; NEWBORN; NUCLEOTIDE SEQUENCE; PATHOLOGY; PATHOPHYSIOLOGY; PENETRANCE; PRESCHOOL CHILD; PREVALENCE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES; ATYPICAL HEMOLYTIC UREMIC SYNDROME; BASE SEQUENCE; BLOOD PROTEINS; CHILD; CHILD, PRESCHOOL; COMPLEMENT C3B INACTIVATOR PROTEINS; COMPLEMENT FACTOR H; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HAPLOTYPES; HUMANS; INFANT; INFANT, NEWBORN; KIDNEY; MALE; MOLECULAR SEQUENCE DATA; MUTATION; MUTATION RATE; PENETRANCE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; RISK FACTORS; SPAIN; YOUNG ADULT;

EID: 84940956200     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2015.06.021     Document Type: Article

References (39)

1. Abarrategui-Garrido C., Martínez-Barricarte R., López-Trascasa M., Rodríguez de Córdoba S., Sánchez-Corral P. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 2009, 114:4261-4271.
2. Blanc C., Roumenina L.T., Ashraf Y., Hyvärinen S., Sethi S.K., Ranchin B., Niaudet P., Loirat C., Gulati A., Bagga A., Fridman W.H., Sautès-Fridman C., Jokiranta T.S., Frémeaux-Bacchi V., Dragon-Durey M.A. Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. J. Immunol. 2012, 189:3528-3537.
3. Bresin E., Rurali E., Caprioli J., Sanchez-Corral P., Fremeaux-Bacchi V., Rodriguez de Cordoba S., Pinto S., Goodship T.H., Alberti M., Ribes D., Valoti E., Remuzzi G., Noris M., European Working Party on Complement Genetics in Renal Diseases Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J. Am. Soc. Nephrol. 2013, 24:475-486.
4. Caesar J.J.E., Lavender H., Ward P.N., Exley R.M., Eaton J., Chittock E., Malik T.H., Goicoechea de Jorge E., Pickering M.C., Tang C.M., Lea S.M. Competition between antagonistic complement factors for a single protein on N. meningitidis rules disease susceptibility. eLIFE 2014, 23. 10.7554/eLife.04008.
5. Caprioli J., Castelletti F., Bucchioni S., Bettinaglio P., Bresin E., Pianetti G., Gamba S., Brioschi S., Daina E., Remuzzi G., Noris M., International Registry of Recurrent Familial HUS/TTP Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum. Mol. Genet. 2003, 12:3385-3395.
6. Davila S., Wright V.J., Khor C.C., Sim K.S., Binder A., Breunis W.B., Inwald D., Nadel S., Betts H., Carrol E.D., de Groot R., Hermans P.W., Hazelzet J., Emonts M., Lim C.C., Kujipers T.W., Martinon-Torres F., Salas A., Zenz W., Levin M., Hibberd M.L., International Meningococcal Genetics Consortium Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat. Genet. 2010, 42:772-776.
7. Delvaeye M., Noris M., De Vriese A., Esmon C.T., Esmon N.L., Ferrell G., Del-Favero J., Plaisance S., Claes B., Lambrechts D., Zoja C., Remuzzi G., Conway E.M. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2009, 361:345-357.
8. Dragon-Durey M.A., Loirat C., Cloarec S., Macher M.A., Blouin J., Nivet H., Weiss L., Fridman W.H., Frémeaux-Bacchi V. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 2005, 16:555-563.
9. Dragon-Durey M.A., Blanc C., Marliot F., Loirat C., Blouin J., Sautes-Fridman C., Fridman W.H., Fremeaux-Bacchi V. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J. Med. Genet. 2009, 46:447-450.
10. Dragon-Durey M.A., Sethi S.K., Bagga A., Blanc C., Blouin J., Ranchin B., André J.L., Takagi N., Cheong H.I., Hari P., Le Quintrec M., Niaudet P., Loirat C., Fridman W.H., Fremeaux-Bacchi V. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J. Am. Soc. Nephrol. 2010, 21:2180-2187.
11. Esparza-Gordillo J., Goicoechea de Jorge E., Buil A., Carreras Berges L., López-Trascasa M., Sánchez-Corral P., Rodriguez de Córdoba S. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum. Mol. Genet. 2005, 14:703-712.
12. Fremeaux-Bacchi V., Dragon-Durey M.A., Blouin J., Vigneau C., Kuypers D., Boudailliez B., Loirat C., Rondeau E., Fridman W.H. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J. Med. Genet. 2004, 41:e84.
13. Fremeaux-Bacchi V., Fakhouri F., Garnier A., Bienaimé F., Dragon-Durey M.A., Ngo S., Moulin B., Servais A., Provot F., Rostaing L., Burtey S., Niaudet P., Deschênes G., Lebranchu Y., Zuber J., Loirat C. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin. J. Am. Soc. Nephrol. 2013, 8:554-562.
14. Goicoechea de Jorge E., Harris C.L., Esparza-Gordillo J., Carreras L., Arranz E.A., Garrido C.A., López-Trascasa M., Sánchez-Corral P., Morgan B.P., Rodríguez de Córdoba S. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc. Natl. Acad. Sci. 2007, 104:240-245.
15. Hageman G.S., Anderson D.H., Johnson L.V., Hancox L.S., Taiber A.J., Hardisty L.I., Hageman J.L., Stockman H.A., Borchardt J.D., Gehrs K.M., Smith R.J., Silvestri G., Russell S.R., Klaver C.C., Barbazetto I., Chang S., Yannuzzi L.A., Barile G.R., Merriam J.C., Smith R.T., Olsh A.K., Bergeron J., Zernant J., Merriam J.E., Gold B., Dean M., Allikmets R. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl. Acad. Sci. 2005, 102:7227-7232.
16. Józsi M., Licht C., Strobel S., Zipfel S.L., Richter H., Heinen S., Zipfel P.F., Skerka C. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008, 111:1512-1514.
17. Kavanagh D., Goodship T.H., Richards A. Atypical hemolytic uremic syndrome. Semin. Nephrol. 2013, 33:508-530.
18. Legendre C.M., Licht C., Muus P., Greenbaum L.A., Babu S., Bedrosian C., Bingham C., Cohen D.J., Delmas Y., Douglas K., Eitner F., Feldkamp T., Fouque D., Furman R.R., Gaber O., Herthelius M., Hourmant M., Karpman D., Lebranchu Y., Mariat C., Menne J., Moulin B., Nürnberger J., Ogawa M., Remuzzi G., Richards T., Sberro-Soussan R., Severino B., Sheerin N.S., Trivelli A., Zimmerhackl L.B., Goodship T., Loirat C. Terminal complement inhibitor Eculizumab in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2013, 368:2169-2181.
19. Lemaire M., Frémeaux-Bacchi V., Schaefer F., Choi M., Tang W.H., Le Quintrec M., Fakhouri F., Taque S., Nobili F., Martinez F., Ji W., Overton J.D., Mane S.M., Nürnberg G., Altmüller J., Thiele H., Morin D., Deschenes G., Baudouin V., Llanas B., Collard L., Majid M.A., Simkova E., Nürnberg P., Rioux-Leclerc N., Moeckel G.W., Gubler M.C., Hwa J., Loirat C., Lifton R.P. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat. Genet. 2013, 45:531-536.
20. Loirat C., Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J. Rare Dis. 2011, 6:60.
21. Madico G., Welsch J.A., Lewis L.A., McNaughton A., Perlman D.H., Costello C.E., Ngampasutadol J., Vogel U., Granoff D.M., Ram S. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol. 2006, 177:501-510.
22. Maga T.K., Nishimura C.J., Weaver A.E., Frees K.L., Smith R.J. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum. Mutat. 2010, 31:E1445-E1460.
23. Martínez-Barricarte R., Recalde S., Fernández-Robredo P., Millán I., Olavarrieta L., Viñuela A., Pérez-Pérez J., García-Layana A., Rodríguez de Córdoba S., Spanish Multicenter Group on AMD Relevance of complement factor H-related 1 (CFHR1) genotypes in age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2012, 53:1087-1094.
24. Moore I., Strain L., Pappworth I., Kavanagh D., Barlow P.N., Herbert A.P., Schmidt C.Q., Staniforth S.J., Holmes L.V., Ward R., Morgan L., Goodship T.H., Marchbank K.J. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010, 115:379-387.
25. Noris M., Caprioli J., Bresin E., Mossali C., Pianetti G., Gamba S., Daina E., Fenili C., Castelletti F., Sorosina A., Piras R., Donadelli R., Maranta R., van der Meer I., Conway E.M., Zipfel P.F., Goodship T.H., Remuzzi G. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin. J. Am. Soc. Nephrol. 2010, 5:1844-1859.
26. Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2009, 361:1676-1687.
27. Pérez-Caballero D., Gonzalez-Rubio C., Gallardo M.E., Vera M., López-Trascasa M., Rodríguez de Córdoba S., Sánchez-Corral P. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am. J. Hum. Genet. 2001, 68:478-484.
28. Pickering M.C., D'Agati V.D., Nester C.M., Smith R.J., Haas M., Appel G.B., Alpers C.E., Bajema I.M., Bedrosian C., Braun M., Doyle M., Fakhouri F., Fervenza F.C., Fogo A.B., Frémeaux-Bacchi V., Gale D.P., Goicoechea de Jorge E., Griffin G., Harris C.L., Holers V.M., Johnson S., Lavin P.J., Medjeral-Thomas N., Paul Morgan B., Nast C.C., Noel L.H., Peters D.K., Rodríguez de Córdoba S., Servais A., Sethi S., Song W.C., Tamburini P., Thurman J.M., Zavros M., Cook H.T. C3 glomerulopathy: consensus report. Kidney Int. 2013, 84:1079-1089.
29. Rey-Campos J., Rubinstein P., Rodriguez de Cordoba S. A physical map of the human regulator of complement activation gene cluster linking the complement genes CR1, CR2, DAF, and C4BP. J. Exp. Med. 1988, 167:664-669.
30. Richards A., Kemp E.J., Liszewski M.K., Goodship J.A., Lampe A.K., Decorte R., Müslümanoğlu M.H., Kavukcu S., Filler G., Pirson Y., Wen L.S., Atkinson J.P., Goodship T.H. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc. Natl. Acad. Sci. 2003, 100:12966-12971.
31. Rodríguez de Córdoba S., Hidalgo M.S., Pinto S., Tortajada A. Genetics of atypical hemolytic uremic syndrome (aHUS). Semin. Thromb. Hemost. 2014, 40:422-430.
32. Román-Ortiz E., Mendizabal Oteiza S., Pinto S., López-Trascasa M., Sánchez-Corral P., Rodríguez de Cordoba S. Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene. Pediatr. Nephrol. 2014, 29:149-153.
33. Sánchez Chinchilla D., Pinto S., Hoppe B., Adragna M., Lopez L., Justa Roldan M.L., Peña A., López-Trascasa M., Sánchez-Corral P., Rodríguez de Córdoba S. Complement mutations in diacylglycerol kinase-e{open}-associated atypical hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 2014, 9:1611-1619.
34. Sánchez-Corral P., Melgosa M. Advances in understanding the aetiology of atypical Haemolytic Uraemic Syndrome. Br. J. Haematol. 2010, 150:529-542.
35. Sansbury F.H., Cordell H.J., Bingham C., Bromilow G., Nicholls A., Powell R., Shields B., Smyth L., Warwicker P., Strain L., Wilson V., Goodship J.A., Goodship T.H., Turnpenny P.D. Factors determining penetrance in familial atypical haemolytic uraemic syndrome. J. Med. Genet. 2014, 51:756-764.
36. Schneider M.C., Exley R.M., Chan H., Feavers I., Kang Y.H., Sim R.B., Tang C.M. Functional significance of factor H binding to Neisseria meningitidis. J. Immunol. 2006, 176:7566-7575.
37. Strobel S., Abarrategui-Garrido C., Fariza-Requejo E., Seeberger H., Sánchez-Corral P., Józsi M. Factor H-related protein 1 neutralizes anti-factor H autoantibodies in autoimmune hemolytic uremic syndrome. Kidney Int. 2011, 80:397-404.
38. Tortajada A., Yébenes H., Abarrategui-Garrido C., Anter J., García-Fernández J.M., Martínez-Barricarte R., Alba-Domínguez M., Malik T.H., Bedoya R., Cabrera Pérez R., López Trascasa M., Pickering M.C., Harris C.L., Sánchez-Corral P., Llorca O., Rodríguez de Córdoba S. C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J. Clin. Invest. 2013, 123:2434-2446.
39. Zipfel P.F., Edey M., Heinen S., Jòzsi M., Richter H., Misselwitz J., Hoppe B., Routledge D., Strain L., Hughes A.E., Goodship J.A., Licht C., Goodship T.H., Skerka C. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet. 2007, 3:e41.